NSAIDs and chemoprevention

被引:190
作者
Rao, CV [1 ]
Reddy, BS [1 ]
机构
[1] Amer Hlth Fdn, Ctr Canc, Inst Canc Prevent, Chemoprevent Program, Valhalla, NY 10595 USA
关键词
D O I
10.2174/1568009043481632
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Several epidemiological, clinical and experimental studies established nonsteroidal anti-inflammatory drugs (NSAIDs) as promising cancer chemopreventive agents. Long-term use of aspirin and other NSAIDs has been shown to reduce the risk of cancer of the colon and other gastrointestinal organs as well as of cancer of the breast, prostate, lung, and skin. Understanding the action of NSAIDs provides substantial insights into the mechanisms by which these unique agents regulate tumor cell growth and enable better strategies for prevention and treatment. NSAIDs restore normal apoptosis and reduce cell proliferation in human adenomatous colorectal polyps, experimental colonic tumors, and in various cancer cell lines that have lost critical genes required for normal function. NSAIDs, particularly selective cyclooxygenase-2 (COX-2) inhibitors such as celecoxib, have been shown to inhibit angiogenesis in cell culture and in rodent models of angiogenesis. Exploration of the multistep process of carcinogenesis has provided substantial insights into the mechanisms by which NSAIDs modulate these events. However, unresolved questions with regard to safety, efficacy, optimal treatment regimen, and mechanism of action Currently limit the clinical application of NSAIDs to the prevention of polyposis in FAP patients. Moreover, the development of safe and effective NSAIDs for chemoprevention is complicated by the potential that rare, serious toxicity may offset the benefit of treatment with these drugs given to healthy individuals who have a low risk of developing the disease. Growing knowledge in this area has brought about innovative approaches using combine actions of NSAIDs with other agents that have different modes of action. It has also led to the development of nitric oxide-releasing NSAIDs, that induce tumor cell apoptosis and compensate for COX function, as a means of increasing efficacy and minimizing toxicity. There is growing optimism for the view that full exploration of the role of NSAIDs in the prevention and treatment of epithelial cancers will serve towards reducing of mortality and morbidity from various cancers.
引用
收藏
页码:29 / 42
页数:14
相关论文
共 157 条
[21]   INITIAL SCREENING FOR CARCINOGENICITY OF COMMONLY USED DRUGS [J].
FRIEDMAN, GD ;
URY, HK .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1980, 65 (04) :723-733
[22]   TREATMENT OF COLONIC AND RECTAL ADENOMAS WITH SULINDAC IN FAMILIAL ADENOMATOUS POLYPOSIS [J].
GIARDIELLO, FM ;
HAMILTON, SR ;
KRUSH, AJ ;
PIANTADOSI, S ;
HYLIND, LM ;
CELANO, P ;
BOOKER, SV ;
ROBINSON, CR ;
OFFERHAUS, GJA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (18) :1313-1316
[23]   NSAID-induced polyp regression in familial adenomatous polyposis patients [J].
Giardiello, FM .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1996, 25 (02) :349-&
[24]   ASPIRIN AND THE RISK OF COLORECTAL-CANCER IN WOMEN [J].
GIOVANNUCCI, E ;
EGAN, KM ;
HUNTER, DJ ;
STAMPFER, MJ ;
COLDITZ, GA ;
WILLETT, WC ;
SPEIZER, FE .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (10) :609-614
[25]   ASPIRIN USE AND THE RISK FOR COLORECTAL-CANCER AND ADENOMA IN MALE HEALTH-PROFESSIONALS [J].
GIOVANNUCCI, E ;
RIMM, EB ;
STAMPFER, MJ ;
COLDITZ, GA ;
ASCHERIO, A ;
WILLETT, WC .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (04) :241-246
[26]   DIETARY FACTORS AND RISK OF COLON-CANCER [J].
GIOVANNUCCI, E ;
WILLETT, WC ;
STUBBS, A .
ANNALS OF MEDICINE, 1994, 26 (06) :443-452
[27]   REDUCED RISK OF LARGE-BOWEL ADENOMAS AMONG ASPIRIN USERS [J].
GREENBERG, ER ;
BARON, JA ;
FREEMAN, DH ;
MANDEL, JS ;
HAILE, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (11) :912-916
[28]  
Grubbs CJ, 2000, CANCER RES, V60, P5599
[29]   Combinations for cancer prevention [J].
Gupta, RA ;
DuBois, RN .
NATURE MEDICINE, 2000, 6 (09) :974-975
[30]  
Harris RE, 1999, ONCOL REP, V6, P71